Regeneron Pharmaceuticals Q3 FY26: where the revenue came from and where it went
The whole income statement of Regeneron Pharmaceuticals for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
Revenue$5.1B
+36% year over year
Gross profit$4.5B
88% margin
Operating profit$2.0B
40% margin
Net profit$1.9B
38% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 5.1 | 100% | +36% |
| Cost of revenue | −0.6 | 12% | |
| Gross profit | 4.5 | 88% margin | +4pp |
| R&D | −1.8 | 35% | −4pp |
| SG&A | −0.7 | 13% | −4pp |
| Operating profit | 2.0 | 40% margin | +13pp |
| Other income, net | 0.2 | ||
| Tax | −0.3 | ||
| Net profit | 1.9 | 38% margin | −1pp |
149 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest